海南瑞泽公告称，公司股票在2025年12月16 - 18日连续三个交易日内日收盘价格跌幅偏离值累计达 20%，属异常波动。经自查，公司前期信息无更正补充，未现重大未公开信息，经营及环境无重大变 化，实控人无应披露重大事项，异常波动期间实控人未买卖股票。另外，副总经理于清池已完成减持 23.1万股计划。截至公告披露日，实控人及其一致行动人质押比例高，存在质押逾期、司法冻结及平 仓、司法拍卖风险。 ...

Core Viewpoint - Huachuang Securities, a subsidiary of Huachuang Yunxin, is involved in a legal dispute with major shareholder Jiang Wei of Guizhou Bailing Pharmaceutical Group regarding a financial rescue plan and stock pledge issues [1][2]. Group 1: Legal Proceedings - Huachuang Securities has filed lawsuits against Jiang Wei and his associates to recover 1.4 billion yuan (approximately 14 billion) from the rescue plan and 361 million yuan (approximately 3.61 billion) from stock pledge loans [2]. - The lawsuits also seek additional payments for fixed income, penalties, and other litigation-related costs [2]. Group 2: Financial Details - The rescue plan involved Huachuang Securities providing 1.4 billion yuan in funding through two asset management plans, acquiring 161 million shares of Guizhou Bailing, which represents 11.54% of the total share capital [1]. - Jiang Wei also pledged an additional 78 million shares and properties valued at approximately 1.143 billion yuan as collateral for the rescue plan [2]. - For the stock pledge loan, Jiang Wei provided additional collateral valued at approximately 263 million yuan [2]. Group 3: Company Status - Guizhou Bailing is currently under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure laws, with the investigation ongoing [2]. - Jiang Wei is identified as the largest shareholder and actual controller of Guizhou Bailing, serving as the chairman of the company [2].